Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
2 "Ashish Agarwal"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Miscellaneous
Patients with celiac disease are at high risk of developing metabolic syndrome and fatty liver
Ashish Agarwal, Alka Singh, Wajiha Mehtab, Vipin Gupta, Ashish Chauhan, Mahendra Singh Rajput, Namrata Singh, Vineet Ahuja, Govind K. Makharia
Intest Res 2021;19(1):106-114.   Published online April 22, 2020
DOI: https://doi.org/10.5217/ir.2019.00136
AbstractAbstract PDFPubReaderePub
Background/Aims
Gluten-free diet has an excess of fats and simple sugars and puts patients with celiac disease at risk of metabolic complications including metabolic syndrome and fatty liver. We assessed prevalence of metabolic syndrome and fatty liver in two cohorts of celiac disease.
Methods
Study was done in 2 groups. In group 1, 54 treatment naïve patients with celiac disease were recruited. Of them, 44 returned after 1-year of gluten-free diet and were reassessed. In group 2, 130 celiac disease patients on gluten-free diet for ≥1 year were recruited. All patients were assessed for anthropometric and metabolic parameters and fatty liver. Metabolic syndrome was defined as per consensus definition for Asian Indians. Fatty liver was defined as controlled attenuation parameter value >263 decibels by FibroScan.
Results
In group 1, of 44 treatment naïve patients with celiac disease, metabolic syndrome was present in 5 patients (11.4%) at baseline and 9 (18.2%) after 1 year of gluten-free diet. Patients having fatty liver increased from 6 patients (14.3%) at baseline to 13 (29.5%) after 1year of gluten-free diet (P=0.002). In group 2, of 130 patients with celiac disease on gluten-free diet for a median duration of 4 years, 30 out of 114 (26.3%) and 30 out of 130 patients (23%) had metabolic syndrome and fatty liver, respectively.
Conclusions
Patients with celiac disease are at high risk of developing metabolic syndrome and fatty liver, which increases further with gluten-free diet. These patients should be assessed for nutritional and metabolic features and counseled about balanced diet and physical activity regularly.

Citations

Citations to this article as recorded by  
  • Comprehensive LC-ESI-HRMS/MS Profiling and Assessment of Texture, Predicted Glycaemic Index, Antioxidant Activity and Digestive Enzyme Inhibition of Gluten- and Lactose-Free Cookies Enriched with Pomegranate By-Products
    Roberta Pino, Rosa Tundis, Vincenzo Sicari, Antonio Mincione, Antonio Gattuso, Chiara La Torre, Alessia Fazio, Sonia Piacente, Milena Masullo, Antonietta Cerulli, Monica Rosa Loizzo
    Foods.2026; 15(3): 457.     CrossRef
  • Dietary assessments in individuals living with coeliac disease: key considerations
    Anne R. Lee, Melinda Dennis, Jessica Lebovits, Lori Welstead, Ritu Verma, Amelie Therrien, Benjamin Lebwohl
    Journal of Human Nutrition and Dietetics.2025;[Epub]     CrossRef
  • Exploring the link between celiac disease and obesity: a potential role of gut microbiome
    Sunaina Addanki, Anastasia Mashukova, Arkene Levy
    Intestinal Research.2025; 23(2): 193.     CrossRef
  • Raman Hyperspectroscopy and Chemometric Analysis of Blood Serum for Diagnosing Celiac Disease in Adults
    Entesar Al-Hetlani, Lamyaa M. Almehmadi, Igor K. Lednev
    Photonics.2025; 12(6): 553.     CrossRef
  • The Gluten-Free Diet for Celiac Disease
    Kendra Weekley, David Gardinier, Anne R. Lee, Vanessa Weisbrod
    Gastrointestinal Endoscopy Clinics of North America.2025; 35(4): 753.     CrossRef
  • Towards personalized microbial therapies for metabolic alterations in celiac disease
    Alejandro Borrego-Ruiz, Juan J. Borrego
    Exploration of Digestive Diseases.2025;[Epub]     CrossRef
  • Effects of gluten-free diet on metabolic syndrome components and anthropometric indices in patients with nonalcoholic fatty liver disease: An open-label randomized clinical trial
    Maziar Jazayeri, Rasoul Zarrin, Afshin Mohammadi, Mohammad Reza Pashaei, Sajjad Ahmadpour
    Arab Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Hepatic Steatosis and Diet in Adult Celiac Disease: A Cross-Sectional Study
    Míra Zsófia Peresztegi, Zsolt Szakács, Nelli Farkas, Gábor Szekeres, Nándor Faluhelyi, Krisztina Hagymási, Gyula Pásztor, Zsófia Vereczkei, Petra Fülöp, Szilvia Lada, Sarolta Dakó, Eszter Dakó, Judit Bajor
    Nutrients.2025; 17(22): 3577.     CrossRef
  • Celiac Disease as a Model of Intestinal Malnutrition: Mechanisms and Nutritional Management
    Vanessa Nadia Dargenio, Nicoletta Sgarro, Giovanni La Grasta, Martina Begucci, Stefania Paola Castellaneta, Costantino Dargenio, Leonardo Paulucci, Ruggiero Francavilla, Fernanda Cristofori
    Nutrients.2025; 17(23): 3741.     CrossRef
  • Correlations Between Obesity and Autoimmune Diseases
    Anatoly I. Khavkin, Valeriya P. Novikova, Andrew V. Nalyotov, Ludmila A. Podorova, Marina Yu. Komissarova, Dmitry I. Masyuta
    Pediatric pharmacology.2025; 22(5): 624.     CrossRef
  • Efficacy of Antiobesity Medications in Patients With Celiac Disease on a Gluten-free Diet
    Diego Anazco, Sima Fansa, Wissam Ghusn, Khushboo Gala, Bryan Nicolalde, Elif Tama, Gerardo Calderon, Adam C. Bledsoe, Maria D. Hurtado, Joseph A. Murray, Andres Acosta
    Journal of Clinical Gastroenterology.2024; 58(7): 650.     CrossRef
  • Guidelines for best practices in monitoring established coeliac disease in adult patients
    Luca Elli, Daniel Leffler, Christophe Cellier, Benjamin Lebwohl, Carolina Ciacci, Michael Schumann, Knut E. A. Lundin, Stefania Chetcuti Zammit, Reena Sidhu, Leda Roncoroni, Julio C. Bai, Anne R. Lee, Melinda Dennis, Marie E. Robert, Kamran Rostami, Sheri
    Nature Reviews Gastroenterology & Hepatology.2024; 21(3): 198.     CrossRef
  • Probiotic Interventions in Coeliac Disease: A Systematic Review with a Focus on Cardiovascular Risk
    Lorretta Olu Fagbemi, Carlo Soldaini, Adele Costabile, Sofia Kolida, Carolina Ciacci, Yvonne Jeanes
    Gastrointestinal Disorders.2024; 6(1): 114.     CrossRef
  • Metabolomics and lipidomics signature in celiac disease: a narrative review
    Mohammad Rostami-Nejad, Nastaran Asri, Sajjad Bakhtiari, Ensieh Khalkhal, Sepehr Maleki, Mostafa Rezaei-Tavirani, Somayeh Jahani-Sherafat, Kamran Rostami
    Clinical and Experimental Medicine.2024;[Epub]     CrossRef
  • Coeliac disease and type 2 diabetes risk: a nationwide matched cohort and Mendelian randomisation study
    Shuai Yuan, Dan Leffler, Benjamin Lebwohl, Peter H. R. Green, Jiangwei Sun, Sofia Carlsson, Susanna C. Larsson, Jonas F. Ludvigsson
    Diabetologia.2024; 67(8): 1630.     CrossRef
  • Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease
    Hye Kyung Hyun, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
    European Journal of Gastroenterology & Hepatology.2024; 36(4): 445.     CrossRef
  • The Impact of a Gluten-Free Diet on Pregnant Women with Celiac Disease: Do We Need a Guideline to Manage Their Health?
    Yeliz Serin, Camilla Manini, Pasqualino Amato, Anil K. Verma
    Gastrointestinal Disorders.2024; 6(3): 675.     CrossRef
  • The Effects of Gluten-free Diet on Body Mass Indexes in Adults with Celiac Disease
    Noam Peleg, Yaron Niv, Ram Dickman, Doron Boltin, Alex Krauthammer, Michal Herman-Edelstein, Nidal Issa, Jacob E. Ollech, Tom Konikoff, Rachel Gingold-Belfer
    Journal of Clinical Gastroenterology.2024; 58(10): 989.     CrossRef
  • Nutrition Assessment and Management in Celiac Disease
    M. Ines Pinto-Sanchez, Jedid-Jah Blom, Peter R. Gibson, David Armstrong
    Gastroenterology.2024;[Epub]     CrossRef
  • Celiac disease - a pluripathological model in pediatric practice
    Vasile Valeriu Lupu, Maria Oana Sasaran, Elena Jechel, Iuliana Magdalena Starcea, Ileana Ioniuc, Adriana Mocanu, Solange Tamara Rosu, Valentin Munteanu, Alin Horatiu Nedelcu, Ciprian Danielescu, Delia Lidia Salaru, Anton Knieling, Ancuta Lupu
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Patients with Celiac Disease Have High Prevalence of Fatty Liver and Metabolic Syndrome
    Nishant Aggarwal, Ashish Agarwal, Hasan Alarouri, Vignesh Dwarakanathan, Sana Dang, Vineet Ahuja, Govind K. Makharia
    Digestive Diseases and Sciences.2024; 69(8): 3029.     CrossRef
  • Past, Present, and Future of Noninvasive Tests to Assess Gluten Exposure, Celiac Disease Activity, and End-Organ Damage
    Jocelyn A. Silvester, Luca Elli, Chaitan Khosla, Jason A. Tye-Din
    Gastroenterology.2024; 167(1): 159.     CrossRef
  • The Economic Iceberg of Celiac Disease: More Than the Cost of Gluten-Free Food
    Soran R. Bozorg, Anne R. Lee, Karl Mårild, Joseph A. Murray
    Gastroenterology.2024;[Epub]     CrossRef
  • Gluten-free foods are expensive and nutritionally imbalanced than their gluten-containing counterparts
    Wajiha Mehtab, Samagra Agarwal, Harsh Agarwal, Anam Ahmed, Ashish Agarwal, Shubham Prasad, Ashish Chauhan, Anjali Bhola, Namrata Singh, Vineet Ahuja, Anita Malhotra, Govind K Makharia
    Indian Journal of Gastroenterology.2024; 43(3): 668.     CrossRef
  • Letter: Breaking new ground—Understanding the role of ATI‐free diet in managing MASLD
    Matteo Spertino, Roberta Elisa Rossi, Nicola Pugliese
    Alimentary Pharmacology & Therapeutics.2024; 60(2): 302.     CrossRef
  • Celiac Disease, Gluten-Free Diet and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Georgiana-Diana Cazac, Bogdan-Mircea Mihai, Gabriela Ștefănescu, Georgiana-Emmanuela Gîlcă-Blanariu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Cristina-Mihaela Lăcătușu
    Nutrients.2024; 16(13): 2008.     CrossRef
  • Gluten-Free Diet—What’s Good for Celiac Disease Can Be Bad for Metabolism
    Kathleen Viveiros, Sonal Kumar
    Digestive Diseases and Sciences.2024; 69(8): 2721.     CrossRef
  • Influence of a structured, 1-year-long dietary intervention regarding body composition and cardiovascular risk (ARCTIC) in coeliac disease: a protocol of a multicentre randomised controlled trial
    Zsófia Vereczkei, Zsolt Szakács, Míra Zsófia Peresztegi, Klára Lemes, Krisztina Hagymási, Sarolta Dakó, Eszter Dakó, Szilvia Lada, Nándor Faluhelyi, Gábor Szekeres, Gyula Pásztor, Nelli Farkas, Gabriella Pár, Emese Mezősi, Judit Bajor
    BMJ Open.2024; 14(10): e084365.     CrossRef
  • The prevalence of obesity and underweight in celiac patients at the time of diagnosis: a systematic review and meta-analysis
    Farzad Maleki, Marjan Hosseinpour, Ali Delpisheh, Mansour Bahardoust, Fatemeh Hajizadeh-Sharafabad, Mohammad Reza Pashaei
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Reuse of Almond Skin to Formulate a New Gluten- and Lactose-Free Bakery Product
    Lucia Francesca Vuono, Vincenzo Sicari, Antonio Mincione, Rosa Tundis, Roberta Pino, Natale Badalamenti, Maurizio Bruno, Francesco Sottile, Sonia Piacente, Luca Settanni, Monica Rosa Loizzo
    Foods.2024; 13(23): 3796.     CrossRef
  • Celiac Disease and Liver Damage: The Gut–Liver Axis Strikes Back (Again)? A Retrospective Analysis in the Light of a Literature Review
    Aurelio Seidita, Federica Latteri, Mirco Pistone, Alessandra Giuliano, Luca Bertoncello, Giorgia Cavallo, Marta Chiavetta, Francesco Faraci, Alessia Nigro, Alessandro Termini, Laura Verona, Agnese Ammannato, Salvatore Accomando, Francesca Cavataio, Maria
    Nutrients.2024; 17(1): 85.     CrossRef
  • Gluten: do only celiac patients benefit from its removal from the diet?
    Laryssa Rosa de Sousa Franckilin, Anna Clara Paiva Menezes Dos Santos, Flávio Eduardo Dias Araújo Freitas, Isabela Garbazza Vieira, Carlos Eduardo de Freitas Jorge, Daniela Godoy Neri, Maria Vitória Cota de Abreu, Janaina Koenen Fonseca, Renato Guimarães
    Food Reviews International.2023; 39(7): 4388.     CrossRef
  • Risk of obesity during a gluten-free diet in pediatric and adult patients with celiac disease: a systematic review with meta-analysis
    Michele Barone, Andrea Iannone, Fernanda Cristofori, Vanessa Nadia Dargenio, Flavia Indrio, Elvira Verduci, Alfredo Di Leo, Ruggiero Francavilla
    Nutrition Reviews.2023; 81(3): 252.     CrossRef
  • Type 1 Diabetes Mellitus and Autoimmune Diseases: A Critical Review of the Association and the Application of Personalized Medicine
    Mihaela Simona Popoviciu, Nirja Kaka, Yashendra Sethi, Neil Patel, Hitesh Chopra, Simona Cavalu
    Journal of Personalized Medicine.2023; 13(3): 422.     CrossRef
  • Celiac Disease and Cardiovascular Risk: A Retrospective Case-Control Study
    Maria Pina Dore, Sandro Mereu, Pier Sergio Saba, Michele Portoghese, Giovanni Mario Pes
    Journal of Clinical Medicine.2023; 12(6): 2087.     CrossRef
  • Nutritional status, nutrient imbalances, food-related behaviors and dietary supplements use among patients with celiac disease on a gluten free diet in Lebanon: a national cross-sectional study
    Maha Hoteit, Zeinab Chamas, Shaza Assaf, Malek Michael Bouhairie, Abbas Bahr, Romy Daccache, Rami Matar, Mahmoud Hallal, Samer Hotayt, Bilal Hotayt
    F1000Research.2023; 11: 725.     CrossRef
  • Fatty liver and celiac disease: Why worry?
    Janaina Luz Narciso-Schiavon, Leonardo Lucca Schiavon
    World Journal of Hepatology.2023; 15(5): 666.     CrossRef
  • Prevalence of autoimmune, cholestatic and nonalcoholic fatty liver disease in celiac disease
    Asif Ali Hitawala, Ashraf Almomani, Somtochukwu Onwuzo, Antoine Boustany, Prabhat Kumar, Imad Asaad
    European Journal of Gastroenterology & Hepatology.2023; 35(9): 1030.     CrossRef
  • Body Mass Index during Gluten-Free Diet in Patients with Celiac Disease
    Zsófia Vereczkei, Tímea Dergez, Zsuzsanna Fodor, Zsolt Szakács, Judit Bajor
    Nutrients.2023; 15(16): 3517.     CrossRef
  • Obesity and Colorectal Cancer
    Jundeok Lee, Su Young Kim
    The Korean Journal of Gastroenterology.2023; 82(2): 63.     CrossRef
  • Incidentally Discovered Cryptogenic Cirrhosis in a Patient with Untreated Celiac Disease
    Kelli Kosako Yost, Yasmin Alishahi
    Galician Medical Journal.2023; 30(3): E202336.     CrossRef
  • The association of interleukin-10 single nucleotide polymorphisms (rs1800871) and serum levels in Iraqi patients with celiac disease: A case-control study
    Ali Hafedh Abbas, Sahar Taha Hatif, Faiq Isho Gorial, Sara Bayan Ali
    Clinical Epidemiology and Global Health.2023; 24: 101437.     CrossRef
  • Unveiling the Link: A Comprehensive Narrative Review of the Relationship Between Type 1 Diabetes Mellitus and Celiac Disease
    Sanvi Arora, Ayush Tayade, Tanya Bhardwaj, Swanand S Pathak
    Cureus.2023;[Epub]     CrossRef
  • Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysis
    Shalimar, Anshuman Elhence, Bhavik Bansal, Hardik Gupta, Abhinav Anand, Thakur P. Singh, Amit Goel
    Journal of Clinical and Experimental Hepatology.2022; 12(3): 818.     CrossRef
  • Nutritional status, nutrient imbalances, food-related behaviors and dietary supplements use among patients with celiac disease in Lebanon: a national cross-sectional study
    Maha Hoteit, Zeinab Chamas, Shaza Assaf, Malek Michael Bouhairie, Abbas Bahr, Romy Daccache, Rami Matar, Marwa Hallal, Michael Maitar, Mahmoud Hallal, Samer Hotayt, Bilal Hotayt
    F1000Research.2022; 11: 725.     CrossRef
  • Eating Competence and Aspects Related to a Gluten-Free Diet in Brazilian Adults with Gluten-Related Disorders
    Pâmela Mayara de Oliveira, Renata Puppin Zandonadi, Amanda Moreira Veloso Cutrim, Eduardo Yoshio Nakano, Fabiana Lopes Nalon de Queiroz, Raquel B. A. Botelho, Ariana Saraiva, António Raposo
    Nutrients.2022; 14(14): 2815.     CrossRef
  • Nutritional status, nutrient imbalances, food-related behaviors and dietary supplements use among patients with celiac disease on a gluten free diet in Lebanon: a national cross-sectional study
    Maha Hoteit, Zeinab Chamas, Shaza Assaf, Malek Michael Bouhairie, Abbas Bahr, Romy Daccache, Rami Matar, Marwa Hallal, Mahmoud Hallal, Samer Hotayt, Bilal Hotayt
    F1000Research.2022; 11: 725.     CrossRef
  • Multidimensional Disadvantages of a Gluten-Free Diet in Celiac Disease: A Narrative Review
    Martyna Marciniak, Aleksandra Szymczak-Tomczak, Dagmara Mahadea, Piotr Eder, Agnieszka Dobrowolska, Iwona Krela-Kaźmierczak
    Nutrients.2021; 13(2): 643.     CrossRef
  • The Healthy Gluten-Free Diet: Practical Tips to Prevent Metabolic Disorders and Nutritional Deficiencies in Celiac Patients
    Emanuele Rinninella, Marco Cintoni, Pauline Raoul, Silvia Triarico, Tommaso Dionisi, Giovanni Battista Gasbarrini, Antonio Gasbarrini, Maria Cristina Mele
    Gastroenterology Insights.2021; 12(2): 166.     CrossRef
  • Nutritional Properties of Rice Varieties Commonly Consumed in Italy and Applicability in Gluten Free Diet
    Giorgia Vici, Diego Romano Perinelli, Dalia Camilletti, Flora Carotenuto, Luca Belli, Valeria Polzonetti
    Foods.2021; 10(6): 1375.     CrossRef
  • Physical development in children with celiac disease in St. Petersburg
    N. S. Shapovalova, V. P. Novikova, K. A. Klikunova
    Experimental and Clinical Gastroenterology.2021; (4): 116.     CrossRef
  • Celiac disease and obesity: the possibility of comboridity of pathology in children
    V. P. Novikova, V. L. Gritsinskaya, A. I. Khavkin
    Experimental and Clinical Gastroenterology.2021; (4): 124.     CrossRef
  • 16,032 View
  • 249 Download
  • 44 Web of Science
  • 52 Crossref
Close layer
IBD
High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India
Ashish Agarwal, Saurabh Kedia, Saransh Jain, Vipin Gupta, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Venigalla Pratap Mouli, Rajan Dhingra, Govind Makharia, Vineet Ahuja
Intest Res 2018;16(4):588-598.   Published online October 10, 2018
DOI: https://doi.org/10.5217/ir.2018.00023
AbstractAbstract PDFPubReaderePub
Background/Aims
The data on the risk of tuberculosis (TB) reactivation with infliximab (IFX) in patients with inflammatory bowel disease (IBD) from TB endemic countries, like India, is limited. The risk of TB reactivation on IFX and its predictors in patients with IBD was assessed.
Methods
This retrospective review included consecutive patients with IBD who received IFX, and were on follow-up from January 2005 to November 2017. The data was recorded on age/disease duration, indications for IFX, screening for latent tuberculosis (LTB) before IFX, response to IFX, incidence and duration when TB developed after IFX, and type of TB (pulmonary [PTB]/extra-pulmonary [EPTB]/disseminated).
Results
Of 69 patients (22 ulcerative colitis/47 Crohn’s disease; mean age, 35.6±14.5 years; 50.7% males; median follow-up duration after IFX, 19 months [interquartile range, 5.5–48.7 months]), primary non-response at 8 weeks and secondary loss of response at 26 and 52 weeks were seen in 14.5%, 6% and 15% patients respectively. Prior to IFX, all patients were screened for LTB, 8 (11.6%) developed active TB (disseminated, 62.5%; EPTB, 25%; PTB, 12.5%) after a median of 19 weeks (interquartile range, 14.0–84.5 weeks) of IFX. Of these 8 patients’ none had LTB, even when 7 of 8 were additionally screened with contrast-enhanced chest tomography. Though not statistically significant, more patients with Crohn’s disease than ulcerative colitis (14.9% vs. 4.5%, P=0.21), and those with past history of TB (25% vs. 9.8%, P=0.21), developed TB. Age, gender, disease duration, or extraintestinal manifestations could not predict TB reactivation.
Conclusions
There is an extremely high rate of TB with IFX in Indian patients with IBD. Current screening techniques are ineffective and it is difficult to predict TB after IFX.

Citations

Citations to this article as recorded by  
  • ECCO consensus on management of inflammatory bowel disease in low- and middle-income countries
    Alaa El-Hussuna, Almuthe Christina Hauer, Tarkan Karakan, Valerie Pittet, Henit Yanai, Jalpa Devi, Jesus K Yamamoto-Furusho, Ali Reza Sima, Hailemichael Desalegn, Mutaz Idrees Sultan, Vishal Sharma, Hany Shehab, Lamya Mrabti, Natalia Queiroz, Anuraag Jena
    Journal of Crohn’s and Colitis.2026;[Epub]     CrossRef
  • Latent tuberculosis screening for inflammatory bowel disease in tuberculosis endemic region remains porous and suboptimal: A multicentre study
    Daya Krishna Jha, Shilpa Prasad, Arun Valsan, Shubhra Mishra, Priya Nair, Anoop K Koshy, Sonal Singh, Ajay Shankar Prasad, Rajat Shukla, Rizwan Ahamed, Philip Augustine, Kartik Natarajan, Kiran Peddi, Akshay Kulkarni, Sumit Bhatia, Aditya V Pachisia, Prad
    World Journal of Gastroenterology.2026;[Epub]     CrossRef
  • Risk of tuberculosis with anti-TNF therapy in Indian patients with inflammatory bowel disease despite negative screening
    Suprabhat Giri, Sukanya Bhrugumalla, Akash Shukla, Sagar Gangadhar, Srujan Reddy, Sumaswi Angadi, Leela Shinde, Aditya Kale
    Arab Journal of Gastroenterology.2025; 26(1): 33.     CrossRef
  • Assessment and management for latent tuberculosis before advanced therapies for immune-mediated inflammatory diseases: A comprehensive review
    Daya Krishna Jha, Rinkalben Kakadiya, Ananya Sharma, Shankar Naidu, Dipankar De, Vishal Sharma
    Autoimmunity Reviews.2025; 24(3): 103758.     CrossRef
  • Abdominal tuberculosis in a patient with ankylosing spondylitis and infliximab: is the risk still too great? A case report
    Miguel Ángel Moyón, Johan Stephany Añazco, Alex Enrique Vásconez, David Larreategui, María Belén Torres, Natali Moyón, Tatiana Borja, Gabriel Alejandro Molina
    Journal of Surgical Case Reports.2025;[Epub]     CrossRef
  • Tofacitinib in acute severe ulcerative colitis: review addressing seven key unmet needs
    Chuong Dinh Nguyen, Luan Minh Dang, Thong Duy Vo, Hoang Huu Bui, Eun Soo Kim, Joyce Wing Yan Mak, Choon Jin Ooi
    Therapeutic Advances in Gastroenterology.2025;[Epub]     CrossRef
  • Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future
    Manish Manrai, Atul Abhishek Jha, Saurabh Dawra, Aditya Vikram Pachisia
    Future Pharmacology.2024; 4(1): 279.     CrossRef
  • RATE OF INFECTION (TUBERCULOSIS) IN BRAZILIANS IBD PRIVATE PATIENTS: FOLLOW-UP 15 YEARS
    Didia B CURY, Liana C B CURY, Ana C MICHELETTI, Rogério A OLIVEIRA, José J S GONÇALVES
    Arquivos de Gastroenterologia.2024;[Epub]     CrossRef
  • (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review
    Thomas Theo Brehm, Maja Reimann, Niklas Köhler, Christoph Lange
    Clinical Microbiology and Infection.2024; 30(8): 989.     CrossRef
  • “Mitigating tuberculosis reactivation risk in IBD patients on anti-TNF therapy”
    Peeyush Kumar, Saurabh Kedia, Vineet Ahuja
    Arab Journal of Gastroenterology.2024; 25(4): 455.     CrossRef
  • Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review
    Nina Jahnich, Peter D. Arkwright
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
    Kyunghwan Oh, Kee Don Choi, Hyeong Ryul Kim, Tae Sun Shim, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
    Clinical Endoscopy.2023; 56(2): 239.     CrossRef
  • CT in the detection of latent tuberculosis: a systematic review
    N. Moore, M. Maher, G. Murphy, M. O'Callaghan Maher, O.J. O'Connor, M.F. McEntee
    Clinical Radiology.2023; 78(8): 568.     CrossRef
  • Miliary Tuberculosis in a Patient With Ulcerative Colitis Treated With Tofacitinib
    Shruti Verma, Arshdeep Singh, Chandan Kakkar, Ashish Tripathi, Vandana Midha, Ajit Sood
    ACG Case Reports Journal.2023; 10(6): e01066.     CrossRef
  • The Risk of Opportunistic Infections in Patients with Inflammatory Bowel Disease
    Maede Ghanaeipour, Nima Behnaminia, Erfan Khadem, Amirhossein Nafari
    The International Journal of Gastroenterology and Hepatology Diseases.2022;[Epub]     CrossRef
  • Association of Tumor Necrosis Factor α Inhibitor Use with Diagnostic Features and Mortality of Tuberculosis in the United States, 2010–2017
    Shereen S Katrak, Rongxia Li, Sue Reynolds, Suzanne M Marks, Jessica R Probst, Terence Chorba, Kevin Winthrop, Kenneth G Castro, Neela D Goswami
    Open Forum Infectious Diseases.2022;[Epub]     CrossRef
  • Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti‐TNF therapy in tuberculosis endemic region
    Peeyush Kumar, Sudheer K. Vuyyuru, Bhaskar Kante, Pabitra Sahu, Sandeep Goyal, Deepak Madhu, Saransh Jain, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Singh, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Mani Kalaivani, Raju Sharma, Prasenjit
    Alimentary Pharmacology & Therapeutics.2022; 55(11): 1431.     CrossRef
  • Increased Risk of Infection With High Infliximab Trough Level
    Suprabhat Giri, Harish Darak
    Journal of Clinical Gastroenterology.2022; 56(4): 374.     CrossRef
  • Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti‐TNF‐therapy—authors' reply
    Peeyush Kumar, Sudheer Kumar Vuyyuru, Saurabh Kedia, Vineet Ahuja
    Alimentary Pharmacology & Therapeutics.2022; 55(10): 1348.     CrossRef
  • Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective
    Shubhra Mishra, Anuraag Jena, Rinkalben Kakadiya, Vishal Sharma, Vineet Ahuja
    Expert Review of Gastroenterology & Hepatology.2022; 16(8): 737.     CrossRef
  • Tumor necrosis factor-alpha antibody labeled-polyethylene glycol-coated nanoparticles: A mesenchymal stem cells-based drug delivery system in the rat model of cisplatin-induced nephrotoxicity
    Faten A. M. Abo-Aziza, Saleh M. Albarrak, Abdel-Kader A. Zaki, Shaymaa E. El-Shafey
    Veterinary World.2022; : 2475.     CrossRef
  • Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
    Peeyush Kumar, Sudheer K. Vuyyuru, Bhaskar Kante, Saurabh Kedia, Pabitra Sahu, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Kumar, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Govind Makharia, Vineet Ahuja
    Indian Journal of Gastroenterology.2022; 41(5): 446.     CrossRef
  • Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia
    Shu-Chen Wei, Jose Sollano, Yee Tak Hui, Wei Yu, Paul V. Santos Estrella, Lyndon John Q. Llamado, Nana Koram
    Expert Review of Gastroenterology & Hepatology.2021; 15(3): 275.     CrossRef
  • Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents
    Adam Krusiński, Anna Grzywa-Celińska, Katarzyna Szewczyk, Luiza Grzycka-Kowalczyk, Justyna Emeryk-Maksymiuk, Janusz Milanowski, Andrew S. Day
    International Journal of Inflammation.2021; 2021: 1.     CrossRef
  • Long‐term outcomes of anti‐tumor necrosis factor therapy and surgery in nonperianal fistulizing Crohn's disease
    Sudheer K Vuyyuru, Devendra Desai, Saurabh Kedia, Pavan Dhoble, Pabitra Sahu, Bhaskar Kante, Samagra Agarwal, Sawan Bopanna, Rajan Dhingra, Pratap Mouli Venigalla, Raju Sharma, Siddhartha Datta Gupta, Govind Makharia, Peush Sahni, Vineet Ahuja
    JGH Open.2021; 5(4): 420.     CrossRef
  • Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease
    Sanchit Sharma, Arti Gupta, Saurabh Kedia, Samagra Agarwal, Namrata Singh, Sandeep Goyal, Saransh Jain, Vipin Gupta, Pabitra Sahu, Sudheer Kumar Vuyyuru, Bhaskar Kante, Raju Sharma, Rajesh Panwar, Peush Sahni, Govind Makharia, Vineet Ahuja
    Intestinal Research.2021; 19(3): 291.     CrossRef
  • Monitoring frequency of interferon gamma release assay for tuberculosis surveillance following infliximab therapy in patients with Crohn's disease
    Qin Yu Yang, Yi Juan Liu, Ye Xu, Lin Zhang, Cheng Dang Wang
    Journal of Digestive Diseases.2021; 22(8): 473.     CrossRef
  • COVID-19-associated opportunistic infections: a snapshot on the current reports
    Amir Abdoli, Shahab Falahi, Azra Kenarkoohi
    Clinical and Experimental Medicine.2021; 22(3): 327.     CrossRef
  • Efficacy and Safety of Fecal Transplantation Versus Targeted Therapies in Ulcerative Colitis: Network Meta-Analysis
    Sudheer K Vuyyuru, Saurabh Kedia, Mani Kalaivani, Pabitra Sahu, Bhaskar Kante, Peeyush Kumar, Mukesh K Ranjan, Govind Makharia, Ashwin Ananthakrishnan, Vineet Ahuja
    Future Microbiology.2021; 16(15): 1215.     CrossRef
  • A case report of probable ocular tuberculosis following biologics
    Sudha K. Ganesh, Divya Thatikonda
    Indian Journal of Ophthalmology - Case Reports.2021; 1(4): 683.     CrossRef
  • Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea
    Jae Yong Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Ho-Su Lee, Kyung-Wook Jo, Sang Hyoung Park
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Tacrolimus as rescue therapy for steroid-dependent/steroid-refractory ulcerative colitis: Experience from tertiary referral center in India
    Sukrit Sud, Sanjeev Sachdeva, Amarender Singh Puri
    Indian Journal of Gastroenterology.2021; 40(6): 598.     CrossRef
  • Vedolizumab in Inflammatory Bowel Disease: West versus East
    Prasanta Debnath, Pravin M. Rathi
    Inflammatory Intestinal Diseases.2021; 6(1): 1.     CrossRef
  • Antitubercular Therapy Given to Differentiate Crohn’s Disease From Intestinal Tuberculosis Predisposes to Stricture Formation
    Akshita Gupta, Venigalla Pratap Mouli, Srikant Mohta, Bhaskar Kante, Mani Kalaivani, Deepak Madhu, Pabitra Sahu, Sudheer Kumar, Raju Sharma, Peush Sahni, Prasenjit Das, Siddharth Datta Gupta, Govind Makharia, Saurabh Kedia, Vineet Ahuja
    Journal of Crohn's and Colitis.2020; 14(11): 1611.     CrossRef
  • Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India
    Pabitra Sahu, Sudheer K. Vuyyuru, Bhaskar Kante, Ashish Agarwal, Raju Sharma, Prasenjit Das, Rajesh Panwar, Saransh Jain, Sawan Bopanna, Govind Makharia, Saurabh Kedia, Vineet Ahuja
    Indian Journal of Gastroenterology.2020; 39(4): 388.     CrossRef
  • Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model
    Jung Min Kim, Da Hye Kim, Hyo Jeong Park, Hyun Woo Ma, I Seul Park, Mijeong Son, So Youn Ro, Seokmann Hong, Hyo Kyung Han, Soo Jeong Lim, Seung Won Kim, Jae Hee Cheon
    Journal of Nanobiotechnology.2020;[Epub]     CrossRef
  • Long-term outcomes in perianal fistulizing Crohn’s disease in a resource-limited setting: A cohort analysis
    Sudheer K. Vuyyuru, Pabitra Sahu, Saurabh Kedia, Bhaskar Kante, Peeyush Kumar, Mukesh Kumar Ranjan, Raju Sharma, Govind Makharia, S. D. Gupta, Peush Sahni, Vineet Ahuja
    Indian Journal of Gastroenterology.2020; 39(5): 435.     CrossRef
  • Higher risk of tuberculosis in combination therapy for inflammatory bowel disease
    Seong Ji Choi, Min Sun Kim, Eun Sun Kim, Juneyoung Lee, Jae Min Lee, Hyuk Soon Choi, Bora Keum, Yoon Tae Jeen, Hong Sik Lee, Hoon Jai Chun, Chang Duck Kim
    Medicine.2020; 99(44): e22897.     CrossRef
  • Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia
    Rupa Banerjee, Partha Pal, Joyce Wing Yan Mak, Siew C Ng
    The Lancet Gastroenterology & Hepatology.2020; 5(12): 1076.     CrossRef
  • Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study
    Nagesh Kamat, Saurabh Kedia, Uday C. Ghoshal, Abhimanyu Nehra, Govind Makharia, Ajit Sood, Vandana Midha, Varun Gupta, Gourdas Choudhuri, Vineet Ahuja
    Indian Journal of Gastroenterology.2019; 38(1): 44.     CrossRef
  • Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis
    Yu Kyung Jun, Jaeyoung Chun, Eun Ae Kang, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim
    The Korean Journal of Gastroenterology.2019; 74(3): 168.     CrossRef
  • 11,322 View
  • 218 Download
  • 37 Web of Science
  • 41 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP